June 17, 2007 -- In the last week, the news from Chinese biopharma continues to focus on problems with safety. The New York Times ran a story of how difficult it is to track down offenders, and the existence of fake blood protein products in hospitals and clinics was reported, while the Chinese government listed new rules and initiatives to improve safety. Charles River Labs formed a joint venture with Shanghai BioExplorer, China Shenghuo made its IPO, and Legend appears poised to take over Shijiazhuang Pharma. Mindray Medical received 510(k) clearance for two additional medical devices, and Sinovac began a Phase II trial of its bird flu vaccine. More details....
